Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.
Annu Rev Immunol
; 38: 673-703, 2020 04 26.
Article
em En
| MEDLINE
| ID: mdl-32340576
ABSTRACT
Development of improved approaches for HIV-1 prevention will likely be required for a durable end to the global AIDS pandemic. Recent advances in preclinical studies and early phase clinical trials offer renewed promise for immunologic strategies for blocking acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active and passive immunization. Here we review current immunologic strategies for HIV-1 prevention, with a focus on current and next-generation vaccines and bNAbs.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Anticorpos Anti-HIV
/
Infecções por HIV
/
HIV-1
/
Vacinas contra a AIDS
/
Interações Hospedeiro-Patógeno
/
Anticorpos Neutralizantes
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article